A phase IIa, open-label, multi-centre study of TP300 as a single agent first line therapy in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs TP 300 (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 21 Aug 2014 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
- 20 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by UKCRN.
- 25 Nov 2010 New trial record